2024-03-29T11:29:46Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:02001663
2023-11-16T01:56:44Z
499:508:509:1638493189962
Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors
Saito, Takuro
Kurose, Koji
Kojima, Takashi
Funakoshi, Takeru
Sato, Eiichi
Nishikawa, Hiroyoshi
Nakajima, Jun
Seto, Yasuyuki
Kakimi, Kazuhiro
Iida, Shinsuke
Doki, Yuichiro
Oka, Mikio
Ueda, Ryuzo
Wada, Hisashi
solid cancer patients
mogamulizumab
regulatory T cells
clinical trial
CCR4
Tregs infiltrate tumors and inhibit antitumor immunity. KW-0761 (Mogamulizumab) is a humanized anti-CCR4 monoclonal antibody that could eliminate activated Tregs with high immunosuppressive activity that express CCR4. In this phase Ib trial, KW-0761 was used as a cancer immunotherapeutic reagent to deplete Tregs in patients with advanced or recurrent solid CCR4-negative tumors. Thirty-nine patients with solid cancer were treated with KW-0761 at a dose of 0.1 or 1.0 mg/kg. The safety, clinical responses, and effects of Treg depletion were analyzed. Any grade and grade 3–4 treatment-related adverse events (AEs) were observed in 36 (92%) and 14 (36%) out of 39 patients, respectively. All treatment-related AEs were manageable. One and 5 patients achieved a partial response and stable disease, respectively, during treatment and were long survivors. The efficient depletion of Treg in peripheral blood was confirmed in both cohorts. Therefore, the administration of KW-0761 was safe, resulting in the depletion of Tregs in peripheral blood and potential immune responses in patients with solid cancer. The combined use of KW-0761 to deplete Tregs and other immunotherapies is a promising approach to augment immune responses.
departmental bulletin paper
Nagoya University Graduate School of Medicine, School of Medicine
2021-11
application/pdf
Nagoya Journal of Medical Science
4
83
827
840
0027-7622
2186-3326
https://nagoya.repo.nii.ac.jp/record/2001663/files/15-2_Saito.pdf
eng
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International